Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exemestane vs Anastrozole in Advanced Breast Cancer
NCT00143390Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2005
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of exemestane in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Time to Progression up to 2008 days. Started Apr 2005; status: completed.
02
Drugs
exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00143390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143390.